Editas Medicine, Inc. (EDIT) News
Filter EDIT News Items
EDIT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EDIT News Highlights
- For EDIT, its 30 day story count is now at 16.
- Over the past 25 days, the trend for EDIT's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about EDIT are GENE, DRUG and BASE.
Latest EDIT News From Around the Web
Below are the latest news stories about Editas Medicine Inc that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT)The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30th. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […] |
What Kind Of Investors Own Most Of Editas Medicine, Inc. (NASDAQ:EDIT)?If you want to know who really controls Editas Medicine, Inc. ( NASDAQ:EDIT ), then you'll have to look at the makeup... |
Why Editas Medicine Stock Is Tumbling This WeekShares of Editas Medicine (NASDAQ: EDIT) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. Editas Medicine CEO James Mullen specifically mentioned base editing in his comments at the J. P. Morgan conference and seemed a bit defensive. |
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To These CRISPR StocksCRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology. |
The Gene-Editing Industry Weighs In on Outlook at J.P. Morgan ConferenceCompanies like Intellia Therapeutics and Editas Medicine are saying that this year will bring exciting developments. |
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare ConferenceJames C. Mullen James C. Mullen, Chairman, President, and Chief Executive Officer of Editas Medicine Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022 Company announces new development candidates EDIT-103 for RHO-adRP and EDIT-202 multiplexed iNK cell therapy for solid |
Morgan Stanley Sticks to Their Sell Rating for Editas Medicine (EDIT)In a report released today, Matthew Harrison from Morgan Stanley maintained a Sell rating on Editas Medicine (EDIT – Research Report), with a price target of $24.00. The company's shares closed last Thursday at $24.55. According to TipRanks.com, Harrison is a 5-star analyst with an average return of 11.8% and a 53.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Zentalis Pharmaceuticals, and BioMarin Pharmaceutical. The word on The Street in general, suggests a Hold analyst consensus rating for Editas Medicine with a $49.50 average price target. |
Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website fo |
Editas Medicine: A Speculative Bet on Gene EditingEditas Medicine (EDIT) is an American clinical-stage biotechnology company that is focused on developing therapies based on CRISPR gene-editing technology. The company has facilities in Boulder, Colorado, and is headquartered in Cambridge, Massachusetts. I am neutral on Editas Medicine. Its support from Wall Street analysts and massive upside relative to its consensus price target are offset by its lack of profitability and no clear short-term path to meaningful growth or profitability. (See Analysts’ Top Stocks on TipRanks) Strengths Editas was originally known as Gengine Inc. |
Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price RecentlyIntroduction I am neutral on Editas Medicine (EDIT). The company has exciting gene-editing technology but, in my opinion, does not have a drug pipeline to warrant its current valuation. The company is at a reasonable entry price if you intend to invest. I plan to wait and watch the company... |